Comparison of anti-proliferative effects of AG957, AG490, and STI571 on BCR-ABL-expressing cell lines.
3H-thymidine incorporation in varying concentrations of vehicle AG957, AG490, and STI571 in the presence or absence of growth factor. (A) Comparison of AG957, AG490, and vehicle in presence of IL-3 for the cell line FDbcr210E; 18-hour exposure to inhibitor. (B) Comparison of AG957 and STI571 ± IL-3 for untransfected FDC-P1 cells; 18-hour incubation in inhibitor. (C) Comparison of AG957 and STI571 ± IL-3 for the BCR-ABL-expressing cell line FDbcr210E; 18-hour incubation in inhibitor. (D) Comparison of AG957 and STI571 ± IL-3 for the BCR-ABL-expressing cell line FDbcr210E; 30-minute incubation in inhibitor. (E) Comparison of AG957 and STI571 for the human BCR-ABL-expressing cell line K562; 18-hour incubation in inhibitor in absence of IL-3.
